Information Provided By: 
Fly News Breaks for April 1, 2015
DYAX
Apr 1, 2015 | 07:07 EDT
RBC Capital hiked its price target on Dyax as the firm believes that a Phase IB trial of the company's DX-930 treatment for HAE clearly showed proof-of-concept that it can essentially reduce/ prevent nearly all HAE attacks. The firm thinks the stock could reach $35-$39 in a blue sky, long-term scenario. It keeps an Outperform rating on the stock.
News For DYAX From the Last 2 Days
There are no results for your query DYAX
